Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Man Group plc

Man Group plc grew its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 24.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 315,817 shares of the biopharmaceutical company's stock after buying an additional 61,123 shares during the period. Man Group plc owned approximately 0.26% of Catalyst Pharmaceuticals worth $6,591,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in CPRX. Nuveen Asset Management LLC grew its position in Catalyst Pharmaceuticals by 14.5% in the fourth quarter. Nuveen Asset Management LLC now owns 1,304,391 shares of the biopharmaceutical company's stock worth $27,223,000 after acquiring an additional 165,249 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Catalyst Pharmaceuticals by 3.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,252 shares of the biopharmaceutical company's stock valued at $1,425,000 after buying an additional 2,252 shares during the period. Lazard Asset Management LLC grew its stake in shares of Catalyst Pharmaceuticals by 58.6% during the fourth quarter. Lazard Asset Management LLC now owns 125,343 shares of the biopharmaceutical company's stock valued at $2,614,000 after buying an additional 46,318 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Catalyst Pharmaceuticals by 32.2% in the fourth quarter. Janus Henderson Group PLC now owns 476,023 shares of the biopharmaceutical company's stock worth $9,935,000 after buying an additional 115,832 shares during the period. Finally, Gotham Asset Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 7.8% in the fourth quarter. Gotham Asset Management LLC now owns 38,953 shares of the biopharmaceutical company's stock worth $813,000 after buying an additional 2,812 shares during the period. Institutional investors own 79.22% of the company's stock.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 351,879 shares of company stock worth $8,214,815 over the last ninety days. 10.40% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Trading Up 1.6%

Catalyst Pharmaceuticals stock traded up $0.38 during trading hours on Friday, hitting $24.49. 772,723 shares of the stock traded hands, compared to its average volume of 1,106,163. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.16. The firm's 50-day moving average price is $23.53 and its two-hundred day moving average price is $22.55. The company has a market cap of $2.99 billion, a PE ratio of 20.75, a PEG ratio of 3.31 and a beta of 0.70.

Analysts Set New Price Targets

Several equities analysts recently issued reports on CPRX shares. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Robert W. Baird boosted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.